• English
    • español
    • português (Brasil)
  • português (Brasil) 
    • English
    • español
    • português (Brasil)
  • Entrar
Ver item 
  •   COVID-19
  • Resources in English
  • Technical documents and research evidence on COVID-19
  • Ver item
  •   COVID-19
  • Resources in English
  • Technical documents and research evidence on COVID-19
  • Ver item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Nucleoside inhibitors of Zika virus

 
Thumbnail
Data
2016
Autor
Eyer, Luděk
Nencka, Radim
Huvarová, Ivana
et al.
et al.
Metadata
Mostrar registro completo
Resumo
There is growing evidence that Zika virus (ZIKV) can cause devastating infant brain defects and other neurological disorders in humans. However, no specific antiviral therapy is available at present. We tested a series of 2′-C- or 2′-O-methyl–substituted nucleosides, 2′-C-fluoro-2′-C-methyl–substituted nucleosides, 3′-O-methyl–substituted nucleosides, 3′-deoxynucleosides, derivatives with 4′-C-azido substitution, heterobase-modified nucleosides, and neplanocins for their ability to inhibit ZIKV replication in cell culture. Antiviral activity was identified when 2′-C–methylated nucleosides were tested, suggesting that these compounds might represent promising lead candidates for further development of specific antivirals against ZIKV.
URI
There is growing evidence that Zika virus (ZIKV) can cause devastating infant brain defects and other neurological disorders in humans. However, no specific antiviral therapy is available at present. We tested a series of 2′-C- or 2′-O-methyl–substituted nucleosides, 2′-C-fluoro-2′-C-methyl–substituted nucleosides, 3′-O-methyl–substituted nucleosides, 3′-deoxynucleosides, derivatives with 4′-C-azido substitution, heterobase-modified nucleosides, and neplanocins for their ability to inhibit ZIKV replication in cell culture. Antiviral activity was identified when 2′-C–methylated nucleosides were tested, suggesting that these compounds might represent promising lead candidates for further development of specific antivirals against ZIKV.
Collections
  • Technical documents and research evidence on COVID-19

Navegar

Todo o repositórioComunidades e ColeçõesPor data do documentoAutoresTítulosCategoriaAssuntosEsta coleçãoPor data do documentoAutoresTítulosCategoriaAssuntos

Minha conta

EntrarCadastro

Organização Pan-Americana da Saúde
Organização Mundial da Saúde. Escritório Regional para as Américas.
525 Twenty-third Street, N.W., Washington, D.C. 20037, Estados Unidos

Notas importantes sobre el contenido (Disclaimer)

Links

  • OPAS Doença por Coronavírus ‎‎(COVID-19)‎
  • OPAS/BIREME Vitrines do Conhecimento COVID-19

  • Biblioteca Digital da OPAS (IRIS PAHO)
  • Biblioteca Virtual em Saúde (BVS)
  • Global Index Medicus (GIM)